Worcester, MA, Dec. 10, 2014 – CellMosaic Inc. announced today that the United States Patent and Trademark Office (USPTO) issued its first patent on AqT™ molecules. The newly issued U.S. patent Serial No. 8,907,079 entitled “Crosslinking reagents, macromolecules, therapeutic conjugates, and synthetic methods thereof” describes various AqT™ molecules and architectures based on sugar alcohols. These molecules are used for preparing bioconjugation-based research reagents with enhanced water solubility and activities, diagnostic reagents for signal amplification, and target-specific drugs, such as antibody-drug conjugates, and for delivering therapeutic biopolymers and small molecules.
“We are pioneers in using sugar alcohol molecules to assemble novel architectures for bioconjugation-based drug development and drug delivery. Due to the diversified structures of sugar alcohols and the methodologies we have been developing over the years for assembling these molecules, the possibilities of customizing AqT™ architectures for drug development in various disease fields are endless.” said Dr. Yumei Huang, founder and CEO of CellMosaic. “We are pleased that the first patent for the AqT™ molecules was granted within one year of filing. With this, CellMosaic is fully committed to unveiling the power of sugar alcohol chemistry, commercialize novel biomaterials for drug development and research usage, and developing AqT™-based therapeutics.”
About AqT™ molecules
AqT™ molecules are new entities designed and created at CellMosaic based on sugar alcohol monomers. Sugar alcohols occur naturally in foods and are often used as ingredients in sweeteners. Sugar alcohol is structurally analogous to polyethylene glycol (PEG), but it is 64-times more hydrophilic than PEG of a comparable size. Sugar alcohol is also a neutral compound and has potentially low or no immunogenicity. AqT™ molecules allow maximum flexibility in building and generating novel drug conjugates with enhanced therapeutic profiles due to their super-hydrophilic, mono-disperse, and multifunctional natures. For example, shorter AqTÔ cross linkers allow convenient linking of hydrophobic drug molecules to a targeting biopolymer in water without a loss of activity, improving efficacy in vivo.When used to label a therapeutic biopolymer, AqT™ polymer can increase the protein’s stability in the circulation, reduce its immunogenicity, and decrease the frequency of dosing. The mono-dispersed AqT™ polymer makes a homogeneous conjugate possible; thus, the conjugate manufacturing process is predictable and easy to control. The AqT™ polymer can also be designed with multiple conjugation sites for loading hydrophobic chemotherapeutic agents. This will greatly increase the solubility and stability of hydrophobic drugs and increase the amount of drug delivered to tumors, reducing undesirable side effects and the frequency of dosing.
About CellMosaic, Inc.
CellMosaic, Inc. is an innovator and leader in bioconjugation and crosslinking technologies. Several key technologies are being developed at CellMosaic, including oxLink™ technologies for studying protein–protein interactions; superhydrophilic AqT™ linkers for conjugation of antibody/protein/peptide/oligo with small molecule drugs; biocompatible, biodegradable, mono-dispersed AqT™ polymers for modification of protein/peptide/oligo drugs and preparation of highly loaded small molecule drugs for better delivery; and bioconjugation platform technologies involving screening, labeling/crosslinking, purification, and analysis of any bioconjugate. The company is also actively engaged in serving biological communities by providing custom synthesis of high quality bioconjugate products. Partnerships and licensing options are available for developing AqT™-based bioconjugate drugs. For more information, please contact Yumei Huang, President & CEO at yhuang@cellmosaic.com or 508-770-8030.
oxLink™, AqueaTether™, and AqT™ are trademarks of CellMosaic, INC
For more information, please visit www.cellmosaic.com